Live Breaking News & Updates on Travisc Mickle|Page 4

Stay updated with breaking news from Travisc mickle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

KemPharm : to Present at the Benzinga Healthcare Small Cap Conference

KemPharm : to Present at the Benzinga Healthcare Small Cap Conference
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Travisc Mickle , Jason Rando , Maureen Mcenroe , Kempharm Inc , Globenewswire Inc , Chief Executive Officer , Healthcare Small Cap Conference , Investor Relations , Ligand Activated Therapy , Pharm Contacts ,

KemPharm Issues Letter to Shareholders

KemPharm Issues Letter to Shareholders
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Perry Sternberg , Travisc Mickle , Us Drug Enforcement Administration , Meeting Of Stockholders Kempharm Inc , Us Department Of Health , Human Services , Corium Inc , Drug Administration , Company Annual Meeting On , Exchange Commission , Securities Exchange , Kempharm Inc , Fellow Shareholders , Gurnet Point Capital , Nasdaq Capital Market , Differentiated Product Nearing Commercial , Licensing Agreement , New Chemical , Orange Book , Enforcement Administration , Stimulant Use Disorder , Investigational New Drug , Restructuring Removes Debt , Strengthens Balance , Annual Meeting , Chief Executive ,

KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital

KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Perry Sternberg , Travisc Mickle , Us Drug Enforcement Administration , Corium Inc , Drug Administration , Shire Plc , Exchange Commission , Head Of The Neuroscience Division , Securities Exchange , Kempharm Inc , Takeda Pharmaceutical Corporation , Wall Street , Receive Additional Near Term , Milestone Payment Following , Commave Therapeutics , Gurnet Point Capital , License Agreement , Chief Commercial , Neuroscience Division , Takeda Pharmaceutical Corporation Limited , Enforcement Administration , Ligand Activated Therapy , Concerning Forward Looking Statements , Securities Act , Securities Exchange Act , Annual Report ,

KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

Message :
Required fields
Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales
Conference Call and Live Audio Webcast Scheduled for Today, Thursday, April 8, at 4:30 p.m. ET
CELEBRATION, Fla., April 08, 2021 (GLOBE NEWSWIRE) KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an amendment to the definitive collaboration and license agreement (the License Agreement) with an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the life sciences and medical technology sectors. The License Agreement provides for an exclusive worldwide license to develop, manufacture and commercialize KemPharm’s product candidates containing serdexmethylphenidate (SDX) and d-methylphenidate (d-MPH), including AZSTARYS™ (formerly referred to as KP415), a once-d ....

United States , Jason Rando Maureen Mcenroe , Travisc Mickle , Us Drug Enforcement Administration , American Psychiatric Association , Corium Inc , Drug Administration , Exchange Commission , Securities Exchange , Kempharm Inc , Amendment Increases Total Potential Regulatory , Sales Milestone Payments , New Top Level Tier , Live Audio Webcast Scheduled , License Agreement , Gurnet Point Capital , Enforcement Administration , Call Information , Investor Relations , Attention Deficit Hyperactivity Disorder , Ligand Activated Therapy , Psychiatric Association , Clinical Child , Adolescent Psychology , Concerning Forward Looking Statements , Securities Act ,

KemPharm to Present at the 33rd Annual Roth Conference

During the pre-recorded virtual presentation, Dr. Mickle will provide an overview of KemPharm’s corporate achievements and potential milestones, including the U.S. Food and Drug Administration’s (FDA) recent approval of AZSTARYS™ (formerly known as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older. AZSTARYS consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.
The complete label for AZSTARYS, including prescribing information and important safety information, may be found at https://kempharm.com/wp-content/uploads/2021/03/AZSTARYS-Master-Label-Final 20210302.pdf.
About KemPharm:
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT ....

Jason Rando Maureen Mcenroe , Travisc Mickle , Drug Administration , Exchange Commission , Securities Exchange , Kempharm Inc , Annual Roth Conference , Annual Roth , Ligand Activated Therapy , Stimulant Use Disorder , Concerning Forward Looking Statements , Securities Act , Securities Exchange Act , Annual Report , Quarterly Report , Pharm Contacts , Maureen Mcenroe , Other Otc Kmph , பரிமாற்றம் தரகு , பத்திரங்கள் பரிமாற்றம் , ஆண்டு ரோத் மாநாடு , ஆண்டு ரோத் , பற்றி முன்னோக்கி பார்க்கிறது அறிக்கைகள் , பத்திரங்கள் நாடகம் , பத்திரங்கள் பரிமாற்றம் நாடகம் , ஆண்டு அறிக்கை ,